Inovio Pharmaceuticals (INO) Total Current Liabilities (2010 - 2026)

Inovio Pharmaceuticals has disclosed Total Current Liabilities across 17 years of filings, most recently posting $39.9 million for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 25.88% year-over-year to $39.9 million; the TTM figure through Jun 2026 stood at $39.9 million (up 25.88% YoY), while the FY2025 annual figure was $43.7 million, up 23.62% from the prior year.
• Total Current Liabilities came in at $39.9 million for Q2 2026 at Inovio Pharmaceuticals, up from $37.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $131.1 million in Q2 2022 to a low of $23.4 million in Q1 2024.
• Average Total Current Liabilities over 5 years is $51.9 million, with a median of $43.1 million recorded in 2023.
• Year-over-year, Total Current Liabilities plunged 60.38% in 2023 and jumped 197.13% in 2025.
• Over 5 years, Total Current Liabilities stood at $96.9 million in 2022, then sank by 56.05% to $42.6 million in 2023, then retreated by 17.02% to $35.3 million in 2024, then advanced by 23.62% to $43.7 million in 2025, then decreased by 8.6% to $39.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $39.9 million in Q2 2026, $37.9 million in Q1 2026, and $43.7 million in Q4 2025.